Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives

Five percent of patients with cutaneous squamous cell carcinoma develop locally advanced or metastatic disease that is not amenable to definitive surgical or radiation therapy. Cemiplimab, an antibody against programmed death receptor-1, was approved in the United States for the treatment of locally...

Descripción completa

Detalles Bibliográficos
Autores principales: Mager, Layna, Gardeen, Samantha, Carr, David R, Shahwan, Kathryn T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423569/
https://www.ncbi.nlm.nih.gov/pubmed/37581012
http://dx.doi.org/10.2147/CCID.S381471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423569/
https://www.ncbi.nlm.nih.gov/pubmed/37581012
http://dx.doi.org/10.2147/CCID.S381471

Ejemplares similares